In the first quarter of 2024, a total of 62 financing cases occurred in the pharmaceutical manufacturing field across the country, a decrease of 7.46% quarter-on-quarter and a year-on-year increase of 3.33%, involving a disclosed financing amount of 9.898 billion yuan, an increase of 42.44% month-on-month and a year-on-year increase of 33.77%. From the perspective of the field of investment, biological products will still attract the most attention from capital in the first quarter of 2024, with a total of 35 financing cases, involving a financing amount of 5.689 billion yuan, and from the perspective of subdivisions, the investment and financing hotness of pharmaceutical manufacturing in the first quarter is mainly concentrated in the field of small molecules and antibody drugs, with 16 and 11 financing cases respectively, involving financing amounts of 3.125 billion yuan and 3.596 billion yuan respectively. In addition, the financing amount of nuclear drugs and peptide drugs exceeded 1 billion yuan, and the two major subdivisions involved 5 and 8 financing cases respectively.
If you want to view the "Pharmaceutical Manufacturing Investment and Financing Market Report for the First Quarter of 2024 (Full Version)", please add "Institutional Customer Service" to apply for a free trial of RimePEVC products.
Copyright and Disclaimer: The content of this article is written by Laime Research Institute, and its copyright is owned by Shenzhen Laime Data Information Technology Co., Ltd. (hereinafter referred to as Rime or Laimei Data). Without the permission or authorization of Laimai Data, it is forbidden for any unit or person to reproduce, quote, publish, publish, modify or translate the content of this article, and other acts for commercial use. When quoting or reprinting with permission or authorization, the source must be indicated as Rime or Laimai Data. Any unauthorized use of this report will violate the Copyright Law of the People's Republic of China and other laws and regulations as well as the provisions of relevant international conventions, and Laimidata reserves the right to pursue its relevant legal responsibilities.
The content of this article is based on public information or field research data that Laimetry Data believes to be credible, and we strive to be objective and fair in the content of this article, but we do not make any explicit or implied guarantee for the accuracy, reliability, timeliness and completeness of the information, opinions and data contained in this article, and do not assume relevant legal responsibilities. Due to the limitations of research methods and data access resources, the entire content of this report is for reference only and does not constitute any advice on anyone's investment, business decision-making, legal or other operations. Under no circumstances will Laimidata be held liable for any impact or consequences arising from the reference to this report.
- New energy vehicle investment and financing market report for the first quarter of 2024
- Semiconductor investment and financing market report for the first quarter of 2024
- Artificial intelligence investment and financing market report for the first quarter of 2024
- Medical device investment and financing market report for the first quarter of 2024
- Smart Hardware Investment and Financing Market Report for the First Quarter of 2024
- New consumption investment and financing market report for the first quarter of 2024
- Robot investment and financing market report for the first quarter of 2024
- Driven by multiple factors, silicon photonics chips ushered in rapid growth
- Liquid biopsy outlets: exosome diagnosis
- Analysis of the current situation of rural revitalization investment and financing: policies are promoted from top to bottom, and the rapid growth of the industry can be expected in the future
- The industrialization of humanoid robots is accelerating, and it is about to usher in the first year of mass production
- The hot track mentioned by the two sessions - automotive chips
- Marine economy industry investment and financing report
- 【Blockbuster release】Let's find the 2023 PE/VC market report of the Research Institute
- 【Blockbuster Release】2023 Annual Investment Institution Series List
- Hydrogen unicorns hit IPOs again, how will the investment performance of the hydrogen energy track in 2023?
- Shenzhen's "20+8" Industry Report: Laser and Additive Manufacturing
- High-end medical devices in Shenzhen's "20+8" industry report
- Shenzhen's "20+8" industry report
- Shenzhen's "20+8" industry report on great health
- Precision instruments of Shenzhen's "20+8" industry report
- Shenzhen's "20+8" Industry Report on Semiconductors and Integrated Circuits: Where is the Reserve Army?
- Shenzhen's "20+8" Industry Report on Semiconductors and Integrated Circuits: Where is the Power Point?
- The robot of Shenzhen's "20+8" industry report
- Biomedicine in Shenzhen's "20+8" Industry Report